MERCK KGAA

Quris partners with Merck KGaA to evaluate its BioAI platform, integrating AI, miniaturized human tissues, and machine learning for safer drug prediction. This collaboration aims to improve drug development by identifying liver toxicity risks and reducing reliance on animal testing, potentially transforming drug safety, speed, and cost.

Quris partners with Merck KGaA to evaluate its BioAI platform, integrating AI, miniaturized human tissues, and machine learning for safer drug predictions. This collaboration aims to improve drug development by identifying liver toxicity risks and potentially transforming drug safety, speed, and cost.

Merck KGaA partners with Quris to evaluate Quris’ BioAI platform for drug safety prediction, focusing on liver toxicity risks. The platform combines AI, miniaturised human tissues, and machine learning to predict drug safety, aiming to modernise drug discovery and reduce reliance on animal testing.

Evotec and Exscientia used AI to develop an anticancer molecule in 8 months, a process traditionally taking 4-5 years. Exscientia's AI platform accelerates drug discovery, leading to partnerships and significant funding. AI's role in drug discovery is expanding, with companies like Recursion and BenevolentAI leveraging AI for innovative treatments and collaborations with pharma giants.

The pharmaceutical industry evolved from 19th-century roots, with companies like Merck and Pfizer pioneering drug manufacturing. Key developments include insulin, penicillin, and the contraceptive pill. The 21st century has seen advances in immunotherapy and gene therapy, alongside challenges like drug pricing and antibiotic resistance.

CDK8/19 inhibitors, crucial for cancer therapy, showed varied toxicity in studies. Cmpd3 and Cmpd4 exhibited severe systemic toxicity, likely due to off-target effects, not CDK8/19 inhibition. Research highlights the importance of careful off-target analysis and dose selection in developing CDK8/19 inhibitors.

The Oligonucleotide Synthesis market is experiencing rapid growth, driven by advancements in gene therapy, personalized medicine, and next-generation sequencing. Key applications include diagnostics, therapeutics, and data storage. Major players like Thermo Fisher Scientific and Agilent Technologies lead the market, with emerging technologies enabling complex oligonucleotide production.